SHARE
Biologics Contract Development And Manufacturing Organization Cdmo Market

Biologics Contract Development and Manufacturing Organization (CDMO) Market Forecasts to 2028 – Global Analysis By Product (Biosimilars, Biologics), Application (Small Pharma, Big Pharma, Generic Pharma) and By Geography

5.0 (75 reviews)
Published: March 2022 ID: SMRC20499
5.0 (75 reviews)
Published: March 2022 ID: SMRC20499

This report covers the impact of COVID-19 on this global market
Loading...

According to Stratistics MRC, the Global Biologics Contract Development and Manufacturing Organization (CDMO) Market is accounted for $11.01 billion in 2021 and is expected to reach $25.75 billion by 2028 growing at a CAGR of 12.9% during the forecast period. Biologics contract development and manufacturing organizations offer complete services from cell line development to long term commercial supply of biological products. The services include the development of cell lines, upstream and downstream processes, analytical and bioanalytical methods, formulations and quality assessment, and regulatory assistance.

Market Dynamics:

Driver:

Increasing prevalence of various diseases


The prevalence of diseases, such as cancer, neurological disorders, gynecological disorders, ophthalmic disorders, and cardiovascular disorders, is increasing every year. For instance, according to WHO, approximately 8.2 million people die each year due to cancer, accounting for 13.0% of deaths worldwide. Moreover, there will be an estimated 70.0% increase in new cancer cases over the next couple of decades. In such cases, healthcare CDMOs play a vital role in patient care, as many biopharma companies are focusing on the development of novel therapies or first in class products for the treatment of diseases.

Restraint:

In-house production of biologic drugs by top pharma companies


Top pharma companies' propensity toward producing biologic drugs in-house is hampering the growth, as these drugs are high value, high margin products, owing to which large companies are focused on the security of supply, ensuring quality, IP protection of proprietary cell strains, and manufacturing process.

Opportunity:

High consolidation activities by major players


Global biologics contract manufacturing demand will see more consolidation as key players look to inorganic growth strategies to offer integrated solutions to customers. Companies interested in global biologics contract manufacturing demand are seeking to consolidate their position through acquisitions, collaborations, and partnerships with small and medium manufacturers in the market, and expand their product reach. Consolidation activities significantly accelerate a company's strategy and build scale and depth in biologics contract manufacturing demand services.

Threat:

Technical difficulties


It is technically difficult to manufacture products, such as biologics, where tech transfer can be a lengthy and expensive process. A single supplier relationship has the potential to reduce the risk of supply issues. However, the relationship, in turn, helps the CDMO to sell more services to the same customer and lock in products at an earlier stage in their life cycle.

The mammalian segment is expected to be the largest during the forecast period

Using mammalian cells for protein expression can offer the major advantage of being able to produce mammalian proteins with all the correct post-translational modifications that provide a native structure. Mammalian cells like Chinese Hamster Ovary (CHO) cell lines have been among the most preferred and about 70.0% of the protein therapeutics is developed from CHO cells.

The biologics segment is expected to have the highest CAGR during the forecast period

The biologics segment consists of antisense and molecular therapy, recombinant proteins, vaccines, and monoclonal. The favorable safety profile of monoclonal antibodies associated with therapeutic use and high specificity constitutes it as the largest class of biologics in the biopharmaceuticals contract research, development, and manufacturing industry. Increasing demand for antibody-based therapeutics is expected to drive biologics contract manufacturing demand, followed by recombinant proteins, and vaccines. Advanced variants of monoclonal antibodies such as antibody fragment-based products and bispecific antibodies are also steadily gaining traction in the pharmaceutical industry.

Region with largest share:

North America is projected to hold the largest market share owing to the presence of two major economies, such as the United States and Canada. The United States is home to one of the major pharmaceutical industries in the world and commands a significant share of the industry revenue. In addition to this, global biologics CDMO vendors are increasing their investments and are expanding their presence in the region. For instance, in March 2020, Bora Pharmaceuticals expanded its footprint in North America. Over the coming years, CDMOs are expected to expand their presence in the region due to the growing health ailments and aging population.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR due to the various amendments made by regulatory organizations to change clinical trial evaluation standards according to global requirements and many major players are investing in the Asia Pacific. Countries in the Asia Pacific have a dense patient pool and the potential to have advanced medical expertise. The cost of conducting a clinical trial is very low here as compared to western countries. These aforementioned factors will assist the biologics contract development and manufacturing organization market within the region.

Key players in the market

Some of the key players profiled in the Biologics Contract Development and Manufacturing Organization (CDMO) Market include Samsung Biologics, Boehringer Ingelheim Group, Sandoz Biopharmaceuticals (Novartis AG), Parexel International Corporation, Fujifilm Diosynth Biotechnologies USA Inc., AbbVie Contract Manufacturing, Lonza Group, Binex Co. Limited, Rentschler Biotechnologies, Toyobo Co. Limited, AGC Biologics, PRA Health Sciences, Catalent Inc, Wuxi Biologics, and JRS Pharma.

Key developments:

In May 2021: Samsung Biologics announced its plans to add an mRNA vaccine production line at its facility in Songdo, 30 kilometers southwest of Seoul, by the first half of 2022. Messenger RNA (mRNA) vaccines are known for their safety and fast scalability in manufacturing, the company said in a statement, and have been among the first COVID-19 vaccines authorized for use in the United States.

In April 2021: Gene Biotherapeutics partnered with Fujifilm Diosynth Biotechnologies to manufacture Generx [ad5fgf-4] phase 3 angiogenic gene therapy product candidate for refractory angina. Manufacturing operations will be conducted at FDB’s facilities in College Station, TX, where FDB will perform technology transfer and process development activities for Phase 3 clinical and commercial-scale GMP manufacturing of Genereux.

In January 2021: Boehringer Ingelheim entered into a strategic collaboration and licensing agreement with Enara Bio to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen discovery platform. The collaboration combines Boehringer Ingelheim’s approach to tackling cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio’s expertise in cancer antigen identification.

Services Covered:
• Contract Manufacturing Organization (CMO)   
• Contract Research Organization (CRO)    

Types Covered:
• Mammalian      
• Non-Mammalian (Microbial)     

Products Covered:
• Biosimilars
• Biologics

Applications Covered:
• Small Pharma
• Big Pharma
• Generic Pharma

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China       
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary      
        
2 Preface   
    
 2.1 Abstract      
 2.2 Stake Holders     
 2.3 Research Scope     
 2.4 Research Methodology    
  2.4.1 Data Mining    
  2.4.2 Data Analysis    
  2.4.3 Data Validation    
  2.4.4 Research Approach    
 2.5 Research Sources     
  2.5.1 Primary Research Sources   
  2.5.2 Secondary Research Sources   
  2.5.3 Assumptions    
        
3 Market Trend Analysis     
 3.1 Introduction     
 3.2 Drivers      
 3.3 Restraints      
 3.4 Opportunities     
 3.5 Threats      
 3.6 Product Analysis     
 3.7 Application Analysis     
 3.8 Emerging Markets     
 3.9 Impact of Covid-19     
        
4 Porters Five Force Analysis    
 
 4.1 Bargaining power of suppliers    
 4.2 Bargaining power of buyers    
 4.3 Threat of substitutes     
 4.4 Threat of new entrants    
 4.5 Competitive rivalry     
        
5 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By Service
 5.1 Introduction     
 5.2 Contract Manufacturing Organization (CMO)      
 5.3 Contract Research Organization (CRO)        
        
6 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By Type

 6.1 Introduction     
 6.2 Mammalian            
 6.3 Non-Mammalian (Microbial)                    
        
7 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By Product
 7.1 Introduction     
 7.2 Biosimilars     
 7.3 Biologics      
  7.3.1 Antisense and Molecular Therapy  
  7.3.2 Recombinant Proteins   
  7.3.3 Vaccines     
  7.3.4 Monoclonal    
   7.3.4.1 Protein-Based   
   7.3.4.2 Diagnostic   
   7.3.4.3 Therapeutic   
        
8 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By Application
 8.1 Introduction     
 8.2 Small Pharma     
 8.3 Big Pharma     
 8.4 Generic Pharma               
        
9 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By Geography
 9.1 Introduction     
 9.2 North America     
  9.2.1 US     
  9.2.2 Canada     
  9.2.3 Mexico     
 9.3 Europe      
  9.3.1 Germany     
  9.3.2 UK     
  9.3.3 Italy     
  9.3.4 France     
  9.3.5 Spain     
  9.3.6 Rest of Europe    
 9.4 Asia Pacific     
  9.4.1 Japan     
  9.4.2 China     
  9.4.3 India     
  9.4.4 Australia     
  9.4.5 New Zealand    
  9.4.6 South Korea    
  9.4.7 Rest of Asia Pacific    
 9.5 South America     
  9.5.1 Argentina     
  9.5.2 Brazil     
  9.5.3 Chile     
  9.5.4 Rest of South America   
 9.6 Middle East & Africa     
  9.6.1 Saudi Arabia    
  9.6.2 UAE     
  9.6.3 Qatar     
  9.6.4 South Africa    
  9.6.5 Rest of Middle East & Africa    
        
10 Key Developments      
 10.1 Agreements, Partnerships, Collaborations and Joint Ventures 
 10.2 Acquisitions & Mergers    
 10.3 New Product Launch     
 10.4 Expansions     
 10.5 Other Key Strategies     
        
11 Company Profiling      
 11.1 Samsung Biologics     
 11.2 Boehringer Ingelheim Group    
 11.3 Sandoz Biopharmaceuticals (Novartis AG)    
 11.4 Parexel International Corporation   
 11.5 Fujifilm Diosynth Biotechnologies USA Inc.   
 11.6 AbbVie Contract Manufacturing        
 11.7 Lonza Group     
 11.8 Binex Co. Limited     
 11.9 Rentschler Biotechnologies    
 11.10 Toyobo Co. Limited     
 11.11 AGC Biologics     
 11.12 PRA Health Sciences     
 11.13 Catalent Inc     
 11.14 Wuxi Biologics     
 11.15 JRS Pharma       


List of Tables       
1 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Region (2020-2028) ($MN)
2 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2020-2028) ($MN)
3 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2020-2028) ($MN)
4 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2020-2028) ($MN)
5 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2020-2028) ($MN)
6 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2020-2028) ($MN)
7 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2020-2028) ($MN)
8 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2020-2028) ($MN)
9 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2020-2028) ($MN)
10 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2020-2028) ($MN)
11 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2020-2028) ($MN)
12 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2020-2028) ($MN)
13 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2020-2028) ($MN)
14 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2020-2028) ($MN)
15 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Application (2020-2028) ($MN)
16 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small Pharma (2020-2028) ($MN)
17 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2020-2028) ($MN)
18 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharma (2020-2028) ($MN)
19 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2020-2028) ($MN)
20 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2020-2028) ($MN)
21 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2020-2028) ($MN)
22 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2020-2028) ($MN)
23 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2020-2028) ($MN)
24 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2020-2028) ($MN)
25 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2020-2028) ($MN)
26 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2020-2028) ($MN)
27 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2020-2028) ($MN)
28 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2020-2028) ($MN)
29 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2020-2028) ($MN)
30 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2020-2028) ($MN)
31 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2020-2028) ($MN)
32 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2020-2028) ($MN)
33 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Application (2020-2028) ($MN)
34 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small Pharma (2020-2028) ($MN)
35 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2020-2028) ($MN)
36 North America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharma (2020-2028) ($MN)
37 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2020-2028) ($MN)
38 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2020-2028) ($MN)
39 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2020-2028) ($MN)
40 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2020-2028) ($MN)
41 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2020-2028) ($MN)
42 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2020-2028) ($MN)
43 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2020-2028) ($MN)
44 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2020-2028) ($MN)
45 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2020-2028) ($MN)
46 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2020-2028) ($MN)
47 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2020-2028) ($MN)
48 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2020-2028) ($MN)
49 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2020-2028) ($MN)
50 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2020-2028) ($MN)
51 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Application (2020-2028) ($MN)
52 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small Pharma (2020-2028) ($MN)
53 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2020-2028) ($MN)
54 Europe Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharma (2020-2028) ($MN)
55 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2020-2028) ($MN)
56 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2020-2028) ($MN)
57 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2020-2028) ($MN)
58 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2020-2028) ($MN)
59 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2020-2028) ($MN)
60 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2020-2028) ($MN)
61 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2020-2028) ($MN)
62 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2020-2028) ($MN)
63 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2020-2028) ($MN)
64 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2020-2028) ($MN)
65 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2020-2028) ($MN)
66 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2020-2028) ($MN)
67 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2020-2028) ($MN)
68 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2020-2028) ($MN)
69 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Application (2020-2028) ($MN)
70 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small Pharma (2020-2028) ($MN)
71 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2020-2028) ($MN)
72 Asia Pacific Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharma (2020-2028) ($MN)
73 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2020-2028) ($MN)
74 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2020-2028) ($MN)
75 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2020-2028) ($MN)
76 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2020-2028) ($MN)
77 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2020-2028) ($MN)
78 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2020-2028) ($MN)
79 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2020-2028) ($MN)
80 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2020-2028) ($MN)
81 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2020-2028) ($MN)
82 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2020-2028) ($MN)
83 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2020-2028) ($MN)
84 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2020-2028) ($MN)
85 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2020-2028) ($MN)
86 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2020-2028) ($MN)
87 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Application (2020-2028) ($MN)
88 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small Pharma (2020-2028) ($MN)
89 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2020-2028) ($MN)
90 South America Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharma (2020-2028) ($MN)
91 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2020-2028) ($MN)
92 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service (2020-2028) ($MN)
93 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Manufacturing Organization (CMO) (2020-2028) ($MN)
94 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Contract Research Organization (CRO) (2020-2028) ($MN)
95 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Type (2020-2028) ($MN)
96 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Mammalian (2020-2028) ($MN)
97 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Non-Mammalian (Microbial) (2020-2028) ($MN)
98 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Product (2020-2028) ($MN)
99 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biosimilars (2020-2028) ($MN)
100 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics (2020-2028) ($MN)
101 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Antisense and Molecular Therapy (2020-2028) ($MN)
102 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2020-2028) ($MN)
103 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2020-2028) ($MN)
104 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Monoclonal (2020-2028) ($MN)
105 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Application (2020-2028) ($MN)
106 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small Pharma (2020-2028) ($MN)
107 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2020-2028) ($MN)
108 Middle East & Africa Biologics Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharma (2020-2028) ($MN)

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials